Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, type 2 diabetes
Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued
Novo Nordisk is among global pharma leaders in the diabetes and weight loss segments. Read why I think NVO stock is a hold.
Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study
Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.
Wegovy Maker Novo Nordisk Says New Pill Shows 14% Reduction in Heart Attacks, Strokes in Diabetic Patients
The Wegovy maker’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14%, according to a new trial.
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type 2 diabetes. Regulatory filings for Rybelsus expansion expected by 2025.
Novo Nordisk's GLP-1 pill reduces cardiovascular events by 14%
Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.
3h
Novo Nordisk plans label expansion for Rybelsus following Phase III win
The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.
FiercePharma
1d
Novo plots US, EU approval filings after oral semaglutide shows cardio benefits in certain diabetes patients
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
23h
Novo Nordisk: Time To Stay Calm Amid The Recent Plunge (Rating Upgrade)
Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...
STAT
1d
Catalent tries to reassure customers about its deal with Novo Holdings
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
6d
on MSN
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
5h
Whittier Trust Co. Acquires 1,115 Shares of Novo Nordisk A/S (NYSE:NVO)
Whittier Trust Co. increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 2.5% during the third quarter, according to its most recent Form 13F filing with the Securities and ...
20h
Novo Nordisk (0QIU) Gets a Buy from J.P. Morgan
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...
5d
on MSN
Is Novo Nordisk A/S (NVO) the Most Promising Biotech Stock According to Hedge Funds?
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Oral semaglutide
Wegovy
Rybelsus
Catalent
Feedback